Friday, August 5, 2011

Hope... And Reality

 Several items to consider:


1.)  Currently, cancer victims who are refractile to chemotherapy and radiation therapy have limited options - (palliative care). 
This fact makes moot the argument to aggressively pursue treatment - the side effects are as detrimental as the disease.
*****
2.)   Independent testing has confirmed utility with difficult to treat cancer cell lines (U-87 [Astrocytoma, Glioblastoma Multiforme], HEP G2 [Hepatocellular Carcinoma], A 375 [Human Malignant Melanoma]).
Animal testing (mice), has shown no adverse effects - at concentrations thousands of times higher than used for in vitro testing.
*****
3.)   The benefits of commercial development of the NCE's outweigh all perceived risks. 
Independent verification of claims is a straightforward process... There is no downside. In addition to the preferred usage with oncology, these compounds are new chemical entities - specifically - novel alpha amino acids - which have demonstrated antibiotic utility.
*****
4.)   At present, the state-of-the-art regimen for aggressive cancer treatment involve combinations of  surgical excision, chemotherapy, radiation therapy. 
The compound, (S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid,  may eliminate the need for all of these.
*****
5.)  There are 208 separate and distinct cancers. 
The above points suggest a new compound which has potential for therapeutic treatment (primary, combination, adjuvant, prophylactic) of most, if not all, cancers - with no adverse side effects.
*****

The Science

A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.
No anticipated 'side-effects' (e.g. hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).
Wide therapeutic margin.
Possible primary therapy, combination therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.
Excellent likelihood for good stability (and thus long shelf life).
Ease of use and administration - with oral dosing possible.
Low cost of goods.
Antibiotic properties.
New 'reagent' - opens possibilities for all science.
Possible nutritional supplement usage.

Demonstrated mechanism consistent with apoptotic pathway activation - in neoplastic cells.
*****

By activating the apoptosis pathway in a cancer cell leading to the cell death, this compound can be used to treat cancer of any type or origin, such as but not limited to adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma or teratocarcinoma, or the cancer of adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid or uterus.
*****
The science is independently confirmed, reproducible and undisputed... the impediment for this cure is  funding to advance the approval process (CRO toxicology, IND/NDA, human clinical trials). And, yes, it is rewarding to know this compound will save lives.

Regards,

Dennis Wright
drwright442000@yahoo.com